Asimov
@AsimovBio
Followers
6K
Following
184
Media
58
Statuses
258
Asimov programs living cells to advance the design and manufacture of next-generation therapeutics
Boston, MA
Joined May 2017
Our AI-driven cell line and bioprocess design tools consistently deliver 8–11 g/L titers for IgGs and complex multispecifics. Join us tomorrow to learn how we use predictive modeling, rather than trial-and-error, to optimize biologics production:
0
0
4
RT @CorinWagen: I'll be live-tweeting (live-posting?) notes from the Boltz-2 release event at MIT. Initial observation: there's a big turn….
0
76
0
By integrating our CLD with Cytiva’s Fast Trak process development and HyClone media and feed, we're offering:. ✅cell line development (with a titer guarantee of 5g/L for mAbs).✅cell culture media optimization.✅analytical and stability testing.✅scaling to GMP production.
1
0
0
We're parterning with Cytiva to help customers optimize biologics production, from mAbs to multispecifics. We’ve spent years refining our CHO Edge platform in Cytiva’s HyClone media and feed, and now routinely achieve 7-11 g/L clones across biologic modalities.
2
1
6
RT @AsimovPress: Edward Jenner administered the world's first vaccine, for smallpox, in 1796. At the time, smallpox caused nearly 1/5 of AL….
0
9
0
RT @NikoMcCarty: We're now shipping out the second book from @AsimovPress (the first commercial book sold in DNA + print). We're packing an….
0
7
0
RT @NikoMcCarty: A human body is built from 30 trillion cells, which come in a multiplicity of shapes and sizes. The smallest cell, a sperm….
0
105
0
We're partnering with LOTTE BIOLOGICS, a global CDMO, to scale therapeutics manufacturing. Our customers can now transition seamlessly from cell line development using our CHO EDGE system all the way to large-scale GMP production, with faster cycles.
0
8
30
RT @alectricity: Beyond excited to announce our deal with Novo Nordisk! Proud of our team who made this possible. The market and molecula….
0
12
0
We’re proud to share that our CHO Edge System has been licensed by Novo Nordisk, a global leader in healthcare innovation. Forward-thinking companies like Novo Nordisk recognize the importance of accessing cutting-edge technologies to advance therapeutic development. We’re
0
12
37
Major biopharma companies, including Genentech and Gilead, are using AI models to find new medicines, optimize trial designs, and boost manufacturing efficiency. We're featured alongside them in this ITIF report, which touches on some AI tools we're building for gene therapies.
1
5
13
The F.D.A. recently approved Aucatzyl, a CD19 CAR-T therapy for B-ALL leukemia in adults. It joins a handful of other approved CAR-T therapies designed to treat various forms of cancers, including multiple myeloma. But it’s worth looking at Aucatzyl, in particular, because it has
3
4
25
We built a codon optimizer that boosts expression of clinically-relevant transgenes up to 7x. We’ve compared our algorithm to five other codon optimizers available on the market, and results suggest that our algorithm is consistently superior across genes of interest. But what
1
5
63
RT @GENbio: .@AsimovBio and RevOpsis Therapeutics Ink Licensing Deal for Multispecific-Expressing Cell Line. RevOpsis says it is committed….
0
2
0
At least 350+ lentiviral-based gene therapies are in clinical trials. Several have already garnered F.D.A. approval, including a gene therapy for beta-thalassemia, multiple therapies for blood cancers, and another for a rare genetic disease — called CALD — that affects brain.
0
2
16
Today we announced that RevOpsis Therapeutics is licensing our CHO Edge platform to develop and commercialize their first-in-class modular, trispecific biologic molecule for retinal vascular diseases. We’re really excited about this. CHO Edge is an integrated system that enables
0
2
8